Lazaroid compounds prevent early but not late stages of oxidant-induced cell injury: potential explanation for the lack of efficacy of lazaroids in clinical trials
- 1 January 2001
- journal article
- Published by Elsevier in Pharmacological Research
- Vol. 43 (1) , 55-61
- https://doi.org/10.1006/phrs.2000.0740
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injuryJournal of Neurosurgery, 1998
- Too Little, Too Late: Does Tirilazad Mesylate Reduce Fatigue after Subarachnoid Hemorrhage?Neurosurgery, 1998
- A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North AmericaJournal of Neurosurgery, 1997
- ANTIOXIDANT LAZAROID U-74006F IMPROVES RENAL FUNCTION AND REDUCES THE EXPRESSION OF CYTOKINES, INDUCIBLE NITRIC OXIDE SYNTHASE, AND MHC ANTIGENS IN A SYNGENEIC RENAL TRANSPLANT MODELTransplantation, 1996
- A Randomized Trial of Tirilazad Mesylate in Patients With Acute Stroke (RANTTAS)Stroke, 1996
- LazaroidsDrugs, 1995
- Pitfalls and Advances from the International Tirilazad Trial in Moderate and Severe Head InjuryJournal of Neurotrauma, 1995
- Reactive Oxygen Metabolites in Toxic Acute Renal FailureRenal Failure, 1992
- Reactive oxygen species and rat renal epithelial cells during hypoxia and reoxygenationKidney International, 1991
- Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol).Journal of Clinical Investigation, 1984